GLP-1 receptor agonists and cardiovascular-metabolic benefits
study099
10.1016/S0140-6736(17)31205-2
The Lancet
review article
Review of GLP-1 receptor agonists across glycemia, weight, and cardiovascular outcomes.
GLP-1 therapies showed broad metabolic and cardiovascular benefits across trials.
semaglutide
metabolism|cardiometabolic
metabolic-stack
semaglutide-vs-tirzepatide
published